DRB18, combined with the single GLUT-expressing cell lines, the docking study, and nude mouse tumor models, can be used as a lead compound for anticancer therapy and for designing and synthesizing even more efficacious anticancer compounds. The gene discussed is SLC2A1; the disease is neoplasm.